DC in multiple myeloma immunotherapy
- 1 April 2004
- journal article
- review article
- Published by Elsevier BV in Cytotherapy
- Vol. 6 (2), 128-137
- https://doi.org/10.1080/14653240410005357
Abstract
Therapy for patients with multiple myeloma (MM) is currently unsatisfactory and most patients eventually succumb to relapsed disease. DCs are a subset of leukocytes with the capacity to initiate and control the adaptive immune response against many cancers, including MM. In MM patients, in vivo DC function is often abnormal, however, it appears that it can be restored by in vitro manipulation. This has led to the development of DC immunotherapy for MM patients. We review the background research leading to the recognition of an anti-MM immune response, and discuss abnormalities in DC function, potential tumor-associated Ags, and the results of clinical trials of DC immunotherapy in MM patients.Keywords
This publication has 67 references indexed in Scilit:
- Granulocyte-colony stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expressionBlood, 2003
- Preferentially Expressed Antigen of Melanoma (PRAME) in the Development of Diagnostic and Therapeutic Methods for Hematological MalignanciesLeukemia & Lymphoma, 2003
- Prediction of High Affinity Class I-restricted Multiple Myeloma Idiotype Peptide EpitopesLeukemia & Lymphoma, 2003
- Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myelomaBlood, 2002
- Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2000
- Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitutionThe Lancet, 2000
- Idiotypic protein-pulsed dendritic cell vaccination in multiple myelomaInternational Journal of Cancer, 1999
- Dendritic cell immunotherapy for cancer: Application to low‐grade lymphoma and multiple myelomaImmunology & Cell Biology, 1999
- Clonal deletion of thymocytes as a tumor escape mechanismInternational Journal of Cancer, 1998
- Selective loss of CD4+ CD45R+ T cells in peripheral blood of multiple myeloma patientsJournal of Clinical Immunology, 1988